purespring therapeutics limited
purespring therapeutics limited Company Information
Company Number
12543677
Website
-Registered Address
8 bloomsbury street, london, WC1B 3SR
Industry
Research and experimental development on biotechnology
Telephone
02038556324
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
syncona portfolio limited 77.1%
richard francis 5.3%
View Allpurespring therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of PURESPRING THERAPEUTICS LIMITED at £0 based on a Turnover of £0 and 1.39x industry multiple (adjusted for size and gross margin).
purespring therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of PURESPRING THERAPEUTICS LIMITED at £0 based on an EBITDA of £-12.6m and a 5.69x industry multiple (adjusted for size and gross margin).
purespring therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of PURESPRING THERAPEUTICS LIMITED at £36.6m based on Net Assets of £16.3m and 2.24x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Purespring Therapeutics Limited Overview
Purespring Therapeutics Limited is a live company located in london, WC1B 3SR with a Companies House number of 12543677. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in April 2020, it's largest shareholder is syncona portfolio limited with a 77.1% stake. Purespring Therapeutics Limited is a startup, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Purespring Therapeutics Limited Health Check
Pomanda's financial health check has awarded Purespring Therapeutics Limited a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 1 areas for improvement. Company Health Check FAQs
2 Strong
1 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Purespring Therapeutics Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Purespring Therapeutics Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Purespring Therapeutics Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Purespring Therapeutics Limited
- - Industry AVG
Employees
with 30 employees, this is below the industry average (43)
- - Purespring Therapeutics Limited
- - Industry AVG
Pay Structure
on an average salary of £77.3k, the company has an equivalent pay structure (£77.3k)
- Purespring Therapeutics Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- - Purespring Therapeutics Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Purespring Therapeutics Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Purespring Therapeutics Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Purespring Therapeutics Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 428 weeks, this is more cash available to meet short term requirements (33 weeks)
- - Purespring Therapeutics Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 9.9%, this is a lower level of debt than the average (51.2%)
- - Purespring Therapeutics Limited
- - Industry AVG
PURESPRING THERAPEUTICS LIMITED financials
Purespring Therapeutics Limited's latest turnover from December 2022 is 0 and the company has net assets of £16.3 million. According to their latest financial statements, Purespring Therapeutics Limited has 30 employees and maintains cash reserves of £14.7 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|
| Turnover | 0 | 0 | 0 |
| Other Income Or Grants | |||
| Cost Of Sales | |||
| Gross Profit | |||
| Admin Expenses | |||
| Operating Profit | |||
| Interest Payable | 0 | 0 | 0 |
| Interest Receivable | 0 | 0 | 0 |
| Pre-Tax Profit | -12,365,510 | -5,757,717 | -436,142 |
| Tax | -162,810 | -52,611 | 9,342 |
| Profit After Tax | -12,528,320 | -5,810,328 | -426,800 |
| Dividends Paid | 0 | 0 | 0 |
| Retained Profit | -12,528,320 | -5,810,328 | -426,800 |
| Employee Costs | |||
| Number Of Employees | 30 | 15 | 2 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|
| Tangible Assets | 1,491,153 | 1,243,252 | 54,621 |
| Intangible Assets | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 |
| Total Fixed Assets | 1,491,153 | 1,243,252 | 54,621 |
| Stock & work in progress | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 |
| Group Debtors | 747,158 | 189,223 | 0 |
| Misc Debtors | 1,172,099 | 785,396 | 92,235 |
| Cash | 14,710,001 | 11,660,788 | 3,718,205 |
| misc current assets | 0 | 0 | 0 |
| total current assets | 16,629,258 | 12,635,407 | 3,810,440 |
| total assets | 18,120,411 | 13,878,659 | 3,865,061 |
| Bank overdraft | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 |
| Trade Creditors | 915,928 | 887,308 | 189,921 |
| Group/Directors Accounts | 597 | 23,767 | 0 |
| other short term finances | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 |
| other current liabilities | 869,276 | 704,654 | 201,918 |
| total current liabilities | 1,785,801 | 1,615,729 | 391,839 |
| loans | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 |
| total liabilities | 1,785,801 | 1,615,729 | 391,839 |
| net assets | 16,334,610 | 12,262,930 | 3,473,222 |
| total shareholders funds | 16,334,610 | 12,262,930 | 3,473,222 |
| Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|
| Operating Activities | |||
| Operating Profit | |||
| Depreciation | 433,365 | 137,246 | 295 |
| Amortisation | 0 | 0 | 0 |
| Tax | -162,810 | -52,611 | 9,342 |
| Stock | 0 | 0 | 0 |
| Debtors | 944,638 | 882,384 | 92,235 |
| Creditors | 28,620 | 697,387 | 189,921 |
| Accruals and Deferred Income | 164,622 | 502,736 | 201,918 |
| Deferred Taxes & Provisions | 0 | 0 | 0 |
| Cash flow from operations | |||
| Investing Activities | |||
| capital expenditure | |||
| Change in Investments | 0 | 0 | 0 |
| cash flow from investments | |||
| Financing Activities | |||
| Bank loans | 0 | 0 | 0 |
| Group/Directors Accounts | -23,170 | 23,767 | 0 |
| Other Short Term Loans | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 |
| share issue | |||
| interest | 0 | 0 | 0 |
| cash flow from financing | 16,576,830 | 14,623,803 | 3,900,022 |
| cash and cash equivalents | |||
| cash | 3,049,213 | 7,942,583 | 3,718,205 |
| overdraft | 0 | 0 | 0 |
| change in cash | 3,049,213 | 7,942,583 | 3,718,205 |
purespring therapeutics limited Credit Report and Business Information
Purespring Therapeutics Limited Competitor Analysis
Perform a competitor analysis for purespring therapeutics limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other startup companies, companies in WC1B area or any other competitors across 12 key performance metrics.
purespring therapeutics limited Ownership
PURESPRING THERAPEUTICS LIMITED group structure
Purespring Therapeutics Limited has no subsidiary companies.
Ultimate parent company
SYNCONA LTD
#0060836
SYNCONA PORTFOLIO LTD
#0086107
2 parents
PURESPRING THERAPEUTICS LIMITED
12543677
purespring therapeutics limited directors
Purespring Therapeutics Limited currently has 7 directors. The longest serving directors include Dr Christopher Hollowood (Apr 2020) and Mr Moin Saleem-Uddin (Nov 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Christopher Hollowood | England | 49 years | Apr 2020 | - | Director |
| Mr Moin Saleem-Uddin | England | 61 years | Nov 2020 | - | Director |
| Mr Andrew Wilson | 51 years | Nov 2020 | - | Director | |
| Mr Richard Francis | England | 56 years | Mar 2021 | - | Director |
| Dr Michael Kyriakides | United Kingdom | 38 years | Apr 2022 | - | Director |
| Mr Julian Hanak | England | 60 years | Feb 2023 | - | Director |
| Dr John Tsai | England | 57 years | Jun 2023 | - | Director |
P&L
December 2022turnover
0
0%
operating profit
-13m
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
16.3m
+0.33%
total assets
18.1m
+0.31%
cash
14.7m
+0.26%
net assets
Total assets minus all liabilities
Similar Companies
purespring therapeutics limited company details
company number
12543677
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
April 2020
age
4
incorporated
UK
accounts
Small Company
ultimate parent company
previous names
syncona collaboration (s) limited (September 2020)
last accounts submitted
December 2022
address
8 bloomsbury street, london, WC1B 3SR
accountant
-
auditor
RSM UK AUDIT LLP
purespring therapeutics limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to purespring therapeutics limited.
purespring therapeutics limited Companies House Filings - See Documents
| date | description | view/download |
|---|
